Mitoxantrone for worsening multiple sclerosis: Tolerability, toxicity, adherence and efficacy in the clinical setting

Clinical Neurology and Neurosurgery

Volumn 112, Issue 10, 2010, Pages 876-882

  Wundes, Annette ^a   Kraft, George H ^a   Bowen, James D ^a,b   Gooley, Ted A ^a,c   Nash, Richard A ^a,c  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b SWEDISH MEDICAL CENTER   (United States)

^c USA   (United States)

Author keywords

Clinical neurology; Disease modifying therapy; Immunosuppression; Mitoxantrone; Multiple sclerosis

Indexed keywords

MITOXANTRONE;

ADULT; AGED; AMENORRHEA; ARTICLE; CARDIOTOXICITY; DEEP VEIN THROMBOSIS; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSURIA; FATIGUE; FEASIBILITY STUDY; FEMALE; GASTROINTESTINAL SYMPTOM; HAIR DISEASE; HEADACHE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEMATOLOGIC DISEASE; HUMAN; INFECTION; LEUKEMIA; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALAISE; MALE; MENSTRUATION DISORDER; MULTIPLE SCLEROSIS; MYALGIA; NAUSEA; PATIENT COMPLIANCE; RELAPSE; RETROSPECTIVE STUDY; SKIN DISEASE; THORAX DISEASE; VEIN EMBOLISM; VOMITING;

ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS; BLOOD CELL COUNT; CLINICAL PROTOCOLS; DISABILITY EVALUATION; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; MITOXANTRONE; MULTIPLE SCLEROSIS; PATIENT COMPLIANCE; PATIENT DROPOUTS; RECURRENCE; RETROSPECTIVE STUDIES; SAFETY; STROKE VOLUME; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION; YOUNG ADULT;

EID: 78049462007     PISSN: 03038467     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clineuro.2010.07.018     Document Type: Article

References (47)

1. M.G. Brown, S. Kirby, C. Skedgel, J.D. Fisk, T.J. Murray, and V. Bhan How effective are disease-modifying drugs in delaying progression in relapsing-onset MS? Neurology 69 2007 1498 1507
2. M. Rovaris, C. Confavreux, R. Furlan, L. Kappos, G. Comi, and M. Filippi Secondary progressive multiple sclerosis: current knowledge and future challenges Lancet Neurol 5 2006 343 354
3. M. Trojano, F. Pellegrini, A. Fuiani, D. Paolicelli, V. Zipoli, and G.B. Zimatore New natural history of interferon-beta-treated relapsing multiple sclerosis Ann Neurol 61 2007 300 306
4. A. Boster, G. Edan, E. Frohman, A. Javed, O. Stuve, and A. Tselis Intense immunosuppression in patients with rapidly worsening multiple sclerosis: treatment guidelines for the clinician Lancet Neurol 7 2008 173 183
5. E.J. Fox Management of worsening multiple sclerosis with mitoxantrone: a review Clin Ther 28 2006 461 474
6. M. Hutchinson, L. Kappos, P.A. Calabresi, C. Confavreux, G. Giovannoni, and S.L. Galetta The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL J Neurol 256 2009 405 415
7. F. Martinelli Boneschi, M. Rovaris, R. Capra, and G. Comi Mitoxantrone for multiple sclerosis Cochrane Database Syst Rev 2005 CD002127
8. C.H. Polman, P.W. O'Connor, E. Havrdova, M. Hutchinson, L. Kappos, and D.H. Miller A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis N Engl J Med 354 2006 899 910
9. R.A. Rudick, W.H. Stuart, P.A. Calabresi, C. Confavreux, S.L. Galetta, and E.W. Radue Natalizumab plus interferon beta-1a for relapsing multiple sclerosis N Engl J Med 354 2006 911 923
10. T.I. Poirier Mitoxantrone Drug Intell Clin Pharm 20 1986 97 105
11. H.P. Hartung, R. Gonsette, N. Konig, H. Kwiecinski, A. Guseo, and S.P. Morrissey Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial Lancet 360 2002 2018 2025
12. H. Krapf, S.P. Morrissey, O. Zenker, T. Zwingers, R. Gonsette, and H.P. Hartung Effect of mitoxantrone on MRI in progressive MS: results of the MIMS trial Neurology 65 2005 690 695
13. O. Neuhaus, B.C. Kieseier, and H.P. Hartung Therapeutic role of mitoxantrone in multiple sclerosis Pharmacol Ther 109 2006 198 209
14. O.R. Hommes, and H.L. Weiner Results of an international questionnaire on immunosuppressive treatment of multiple sclerosis Mult Scler 8 2002 139 141
15. O.R. Hommes, and H.L. Weiner Clinical practice of immunosuppressive treatments in multiple sclerosis: results of a second international questionnaire J Neurol Sci 223 2004 65 67
16. J.R. Avasarala, A.H. Cross, D.B. Clifford, B.A. Singer, B.A. Siegel, and E.E. Abbey Rapid onset mitoxantrone-induced cardiotoxicity in secondary progressive multiple sclerosis Mult Scler 9 2003 59 62
17. R.G. Ghalie, G. Edan, M. Laurent, E. Mauch, S. Eisenman, and H.P. Hartung Cardiac adverse effects associated with mitoxantrone (Novantrone) therapy in patients with MS Neurology 59 2002 909 913
18. S. Goffette, V. van Pesch, J.L. Vanoverschelde, E. Morandini, and C.J. Sindic Severe delayed heart failure in three multiple sclerosis patients previously treated with mitoxantrone J Neurol 252 2005 1217 1222
19. H. Nagele, M.A. Castel, O. Deutsch, F.M. Wagner, and H. Reichenspurner Heart transplantation in a patient with multiple sclerosis and mitoxantrone-induced cardiomyopathy J Heart Lung Transplant 23 2004 641 643
20. F. Paul, J. Dorr, J. Wurfel, H.P. Vogel, and F. Zipp Early mitoxantrone-induced cardiotoxicity in secondary progressive multiple sclerosis J Neurol Neurosurg Psychiatry 78 2007 198 200
21. J. Killestein, M.L. Van der Meer, J.C. Regelink, P.C. Huijgens, and C.H. Polman Severe cardiac failure in a patient with multiple sclerosis following low-dose mitoxantrone treatment Neurology 74 2010 934
22. J. Dörr, A. Bitsch, K.J. Schmailzl, A. Chan, N. Von Ahsen, and M. Hummel Severe cardiac failure in a patient with multiple sclerosis following low-dose mitoxantrone treatment Neurology 73 2009 991 993
23. V.C. Zingler, M. Nabauer, K. Jahn, A. Gross, R. Hohlfeld, and T. Brandt Assessment of potential cardiotoxic side effects of mitoxantrone in patients with multiple sclerosis Eur Neurol 54 2005 28 33
24. J. Gbadamosi, A. Munchau, C. Weiller, and H. Schafer Severe heart failure in a young multiple sclerosis patient J Neurol 250 2003 241 242
25. W.O. Arruda, M.B. Montu, S. de Oliveira Mde, and R. Ramina Acute myeloid leukaemia induced by mitoxantrone: case report Arq Neuropsiquiatr 63 2005 327 329
26. M. Capobianco, S. Malucchi, S. Ulisciani, C. Fava, G.R. Cambrin, and L. Avonto Acute myeloid leukemia induced by mitoxantrone treatment for aggressive multiple sclerosis Neurol Sci 29 2008 185 187
27. R. Ellis, and M. Boggild Therapy-related acute leukaemia with Mitoxantrone: what is the risk and can we minimise it? Mult Scler 15 2009 505 508
28. R.G. Ghalie, E. Mauch, G. Edan, H.P. Hartung, R.E. Gonsette, and S. Eisenmann A study of therapy-related acute leukaemia after mitoxantrone therapy for multiple sclerosis Mult Scler 8 2002 441 445
29. A.V. Novoselac, S. Reddy, and J. Sanmugarajah Acute promyelocytic leukemia in a patient with multiple sclerosis following treatment with mitoxantrone Leukemia 18 2004 1561 1562
30. A. Pielen, S. Goffette, V. Van Pesch, M. Gille, and C.J. Sindic Mitoxantrone-related acute leukemia in two MS patients Acta Neurol Belg 108 2008 99 102
31. S.A. Sadiq, M. Rammal, and G. Sara Chronic myeloid leukemia associated with mitoxantrone treatment in a patient with MS Mult Scler 14 2008 272 273
32. A. Sumrall, and B. Dreiling Therapy-related acute nonlymphoblastic leukemia following mitoxantrone therapy in a patient with multiple sclerosis J Miss State Med Assoc 48 2007 206 207
33. R. Tanasescu, M. Debouverie, S. Pittion, R. Anxionnat, and H. Vespignani Acute myeloid leukaemia induced by mitoxantrone in a multiple sclerosis patient J Neurol 251 2004 762 763
34. R. Voltz, M. Starck, V. Zingler, M. Strupp, and H.J. Kolb Mitoxantrone therapy in multiple sclerosis and acute leukaemia: a case report out of 644 treated patients Mult Scler 10 2004 472 474
35. A.M. Pascual, N. Téllez, I. Boscá, J. Mallada, A. Belenguer, and I. Abellán Revision of the risk of secondary leukaemia after mitoxantrone in multiple sclerosis populations is required Mult Scler 15 2009 1303 1310
36. National Institute of Health. Common Terminology Criteria for Adverse Events v3.0 (CTCAE). 2006 August 9, 2006. http://ctep.cancer.gov, accessed 08/28/2009.
37. J.J. Marriott, J.M. Miyasaki, G. Gronseth, and P.W. O'Connor Evidence report: the efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology Neurology 74 2010 1463 1470
38. E. Kingwell, M. Koch, B. Leung, S. Isserow, J. Geddes, and P. Rieckmann Cardiotoxicity and other adverse events associated with mitoxantrone treatment for MS Neurology 74 2010 1822 1826
39. M. Boggild Immunosuppression followed by immunomodulation J Neurol Sci 277 2009 S50 S54
40. J. Correale, C. Rush, A. Amengual, and M.T. Goicochea Mitoxantrone as rescue therapy in worsening relapsing-remitting MS patients receiving IFN-beta J Neuroimmunol 162 2005 173 183
41. E. Le Page, and G. Edan Long-term experience with induction treatment regimens in multiple sclerosis J Neurol Sci 277 2009 S46 S49
42. E. Le Page, E. Leray, G. Taurin, M. Coustans, J. Chaperon, and S.P. Morrissey Mitoxantrone as induction treatment in aggressive relapsing remitting multiple sclerosis: treatment response factors in a 5-year follow-up observational study of 100 consecutive patients J Neurol Neurosurg Psychiatry 79 2008 52 56
43. J. Ramtahal, A. Jacob, K. Das, and M. Boggild Sequential maintenance treatment with glatiramer acetate after mitoxantrone is safe and can limit exposure to immunosuppression in very active, relapsing remitting multiple sclerosis J Neurol 253 2006 1160 1164
44. T. Vollmer, H. Panitch, A. Bar-Or, J. Dunn, M.S. Freedman, and S.K. Gazda Glatiramer acetate after induction therapy with mitoxantrone in relapsing multiple sclerosis Mult Scler 14 2008 663 670
45. M. Zaffaroni, A. Rizzo, S.M. Baldini, A. Ghezzi, and G. Comi Induction and add-on therapy with mitoxantrone and interferon beta in multiple sclerosis Neurol Sci 29 2008 S230 S232
46. M. Debouverie, N. Vandenberghe, S.P. Morrissey, R. Anxionnat, S. Pittion-Vouyovitch, and H. Vespignani Predictive parameters of mitoxantrone effectiveness in the treatment of multiple sclerosis Mult Scler 10 2004 407 412
47. G. Edan, D. Miller, M. Clanet, C. Confavreux, O. Lyon-Caen, and C. Lubetzki Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria J Neurol Neurosurg Psychiatry 62 1997 112 118